Approval for generic Semaglutide Injection strengthens CDMO partnership, enabling scalable supply from OneSource’s US FDA-approved Bengaluru facility
Deploys $40 million in Hyderabad; advances APIs, peptides, and global small molecule capabilities
The Alathur facility specializes in the production of Cephalosporin antibiotics
The facility has a potential for capacity expansion up to 2 billion tablets/capsules per year
The company currently supplies one product to the US market that contributes low- single digit revenue to Jubilant Pharmova revenue
The company has already embarked upon significant expansion in Turkey
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
